Loring Wolcott & Coolidge Fiduciary Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$15.5M Sell
61,527
-1,514
-2% -$326K 0.15% 63
2026
Q1
$13.1M Sell
63,041
-1,337
-2% -$297K 0.13% 67
2025
Q4
$14.4M Sell
64,378
-52
-0.1% -$11.8K 0.13% 65
2025
Q3
$14.7M Buy
64,430
+4,263
+7% +$868K 0.13% 64
2025
Q2
$11.2M Sell
60,167
-232
-0.4% -$43.1K 0.1% 68
2025
Q1
$10.7M Buy
60,399
+1,394
+2% +$271K 0.1% 67
2024
Q4
$10.4M Sell
59,005
-1,071
-2% -$197K 0.09% 73
2024
Q3
$11.4M Buy
60,076
+63
+0.1% +$11.8K 0.1% 69
2024
Q2
$10.2M Buy
60,013
+1,643
+3% +$272K 0.09% 68
2024
Q1
$9.8M Sell
58,370
-858
-1% -$148K 0.1% 68
2023
Q4
$9.74M Sell
59,228
-2,016
-3% -$294K 0.1% 69
2023
Q3
$8.77M Sell
61,244
-4,065
-6% -$597K 0.1% 69
2023
Q2
$8.8M Sell
65,309
-338
-0.5% -$49.6K 0.09% 69
2023
Q1
$10.5M Sell
65,647
-1,658
-2% -$253K 0.12% 65
2022
Q4
$10.9M Buy
67,305
+280
+0.4% +$42.9K 0.13% 63
2022
Q3
$8.99M Sell
67,025
-306
-0.5% -$43.9K 0.12% 66
2022
Q2
$10.3M Buy
67,331
+752
+1% +$115K 0.13% 64
2022
Q1
$10.8M Sell
66,579
-3,263
-5% -$474K 0.11% 66
2021
Q4
$9.46M Sell
69,842
-6,219
-8% -$735K 0.09% 72
2021
Q3
$8.21M Buy
76,061
+550
+0.7% +$62.8K 0.08% 73
2021
Q2
$8.51M Buy
75,511
+1,383
+2% +$156K 0.09% 74
2021
Q1
$8.02M Sell
74,128
-6,045
-8% -$647K 0.09% 72
2020
Q4
$8.59M Sell
80,173
-260
-0.3% -$25K 0.1% 67
2020
Q3
$7.04M Sell
80,433
-3,281
-4% -$309K 0.09% 69
2020
Q2
$8.22M Sell
83,714
-1,175
-1% -$103K 0.11% 68
2020
Q1
$6.47M Sell
84,889
-3,695
-4% -$315K 0.11% 68
2019
Q4
$7.84M Sell
88,584
-4,801
-5% -$399K 0.11% 74
2019
Q3
$7.07M Buy
93,385
+1,474
+2% +$101K 0.1% 75
2019
Q2
$6.68M Sell
91,911
-2,573
-3% -$202K 0.1% 79
2019
Q1
$7.61M Sell
94,484
-6,454
-6% -$528K 0.12% 78
2018
Q4
$9.3M Buy
100,938
+1,309
+1% +$115K 0.17% 71
2018
Q3
$9.42M Sell
99,629
-5,847
-6% -$554K 0.15% 76
2018
Q2
$9.77M Sell
105,476
-5,442
-5% -$531K 0.17% 74
2018
Q1
$10.5M Sell
110,918
-306
-0.3% -$33.6K 0.19% 72
2017
Q4
$10.8M Sell
111,224
-319
-0.3% -$30.1K 0.2% 73
2017
Q3
$9.91M Sell
111,543
-1,738
-2% -$132K 0.19% 72
2017
Q2
$7.92M Buy
113,281
+1,474
+1% +$99.1K 0.16% 76
2017
Q1
$7.29M Sell
111,807
-2,877
-3% -$181K 0.15% 82
2016
Q4
$7.18M Buy
114,684
+9,475
+9% +$578K 0.16% 80
2016
Q3
$6.64M Buy
105,209
+67
+0.1% +$4.34K 0.15% 79
2016
Q2
$6.51M Buy
105,142
+6,837
+7% +$417K 0.15% 79
2016
Q1
$5.62M Sell
98,305
-6,120
-6% -$341K 0.13% 86
2015
Q4
$6.19M Buy
104,425
+15,771
+18% +$908K 0.15% 84
2015
Q3
$5.96M Hold
88,654
0.15% 81
2015
Q2
$5.96M Sell
88,654
-5,299
-6% -$346K 0.15% 81
2015
Q1
$5.5M Buy
93,953
+4,285
+5% +$259K 0.14% 85
2014
Q4
$5.87M Sell
89,668
-13,827
-13% -$872K 0.15% 85
2014
Q3
$5.98M Buy
103,495
+1,813
+2% +$101K 0.16% 84
2014
Q2
$5.74M Sell
101,682
-143
-0.1% -$7.5K 0.16% 82
2014
Q1
$5.23M Sell
101,825
-5,430
-5% -$274K 0.14% 90
2013
Q4
$5.66M Sell
107,255
-2,720
-2% -$134K 0.16% 87
2013
Q3
$4.92M Sell
109,975
-75,391
-41% -$3.34M 0.15% 90
2013
Q2
$7.66M Buy
+185,366
New +$8.11M 0.24% 75

Other funds holding ABBV

Loring Wolcott & Coolidge Fiduciary Advisors's ABBV Position: Q2 2026 in Review

Loring Wolcott & Coolidge Fiduciary Advisors reduced its AbbVie (ABBV) stake by 2.4% in Q2 2026, selling an estimated $326K and leaving 61,527 shares worth $15.5M. The position accounts for 0.15% of the portfolio, ranked #63.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 2,841 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Loring Wolcott & Coolidge Fiduciary Advisors held 61,527 shares of AbbVie worth $15.5M as of Q2 2026.
  • Loring Wolcott & Coolidge Fiduciary Advisors sold 1,514 AbbVie shares in Q2 2026, an estimated $326K.
  • AbbVie made up 0.15% of Loring Wolcott & Coolidge Fiduciary Advisors's portfolio in Q2 2026, its #63 holding.
  • Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • 2,841 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.